The Minimal Residual Disease Testing Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Minimal Residual Disease Testing Market?
The Minimal Residual Disease Testing market has seen significant growth recently. The market size was $1.59 billion in 2024, and it is expected to increase to $1.81 billion in 2025. This growth represents a compound annual growth rate (CAGR) of 13.9%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Minimal Residual Disease Testing Industry?
The minimal residual disease testing market is projected to reach a size of $2.96 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.1%.
Download Your Free Sample of the 2025 Minimal Residual Disease Testing Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Minimal Residual Disease Testing Market?
The key drivers in the minimal residual disease testing market are:
• Rise in the occurrence of cancer
• Advancements in therapeutic techniques
• Growing trends in precision medicine
• A shift towards early detection and integration in healthcare systems
Global Market Segmentation: Identifying Major Minimal Residual Disease Testing Industry Segments
The minimal residual disease testing market covered in this report is segmented –
1) By Test Type: DNA - Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
Pre-order the 2025 Minimal Residual Disease Testing Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Minimal Residual Disease Testing Market?
The key trends in the minimal residual disease testing market are:
• Integration of liquid biopsy approaches is a key emerging trend.
• There is an increasing focus on the early detection of relapse.
• Expansion of MRD testing in clinical trials is becoming more prevalent.
• The market is being shaped by increasing adoption in pediatric oncology and collaborations for research and development.
Who Are the Top Competitors & Leading Players in the Minimal Residual Disease Testing Market?
Major companies in the minimal residual disease testing market are:
• Natera Inc.
• Guardant Health Inc.
• Laboratory Corporation of America Holdings
• QIAGEN NV
• F. Hoffmann-La Roche Ltd.
• Bio-Techne Corporation
• Bio-Rad Laboratories Inc.
• Sysmex Corporation
• Exact Sciences Corporation
• GRAIL LLC
• Veracyte Inc.
• Cergentis B.V
• Mdxhealth SA
• NeoGenomics Laboratories Inc.
• Adaptive Biotechnologies
• OPKO Health Inc.
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• PerkinElmer Inc.
• Agilent Technologies Inc.
• ArcherDx Inc.
• Asuragen Inc.
• Becton, Dickinson and Company
• Cepheid Inc.
• Fluidigm Corporation
• Illumina Inc.
• Invitae Corporation
• Janssen Diagnostics LLC
• Luminex Corporation
• Menarini Silicon Biosystems S.p.A.
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the minimal residual disease testing market in 2024
